Soaring Drug Prices Lead to Pharma Industry Finger-Pointing
Comments on the FDA's Biosimilar Interchangeability Draft Guidance Highlight a Growing Need for Clarity
FDA Commissioner Gottlieb Will Work in a Variety of Ways to Contain Drug Prices
UK Authority: Merck Used Illegal Discounts to Defend Against Biosimilar Competition to Remicade
Pfizer's Epogen Biosimilar Called "Highly Similar" to Reference Drug
New Bill in Nevada Spotlights Ambiguity in Insulin Pricing
Certolizumab Responsible for Higher Costs, Pneumonia Rates Than Adalimumab, Etanercept
Celltrion to Play With 4 Brand Names in the EU With Rituximab Biosimilar
EMA Recommends Approval of Sanofi's Insulin Lispro Biosimilar
Janssen Moves to Block Marketing of Renflexis in Suit Against Samsung Bioepis
Biopharma Companies Seek Greater Clarification About FDA's Interchangeability Guidance
US Congressional Delegation Expresses Concern Over Biosimilar Reimbursement Policy
AbbVie Loses Humira Patent Challenge to Coherus
Yet Another Pegfilgrastim Biosimilar Candidate Announces Positive Clinical Study Data
New FDA Commissioner Will Prioritize Opioid Crisis, Drug Pricing
Framework Proposed to Incorporate Biosimilars Education Into Pharmacist Curriculum
Switch from Remicade to Inflectra Did Not Affect Efficacy, Per Danish Study
Biosimilar Competition Has Led to Consistent Price Reduction in Europe
European Guide for Prescribers Assures Safety and Effectiveness of Biosimilars
Strong Early Launch for New Eczema Drug Dupilumab, Despite Price
Three Studies at DDW 2017 Suggest Infliximab Biosimilar Getting Closer to Interchangeability
Senate Confirms Scott Gottlieb as FDA Commissioner
Drug Pricing Not Discussed at White House Meeting of Biotech Execs and NIH
WHO to Start Pilot Prequalification of Biosimilars for 2 Cancer Treatments
ICER Issues Draft Evidence Report on Biologics for Osteoporosis
Celltrion Plans Filing for Biosimilars to Rituximab, Trastuzumab
Biosimilars at the Gates: What's Ahead?
JAMA Viewpoint Explores Barriers to Biosimilar Uptake for Chronic Diseases
The Uncertainty of BPCIA Litigation Strategies and the "Patent Dance"
Biosimilar Uptake Implies Patient Access to Affordable Medication
